trending Market Intelligence /marketintelligence/en/news-insights/trending/bcKvReE-t3SisMuT-I4Myg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Adaptimmune, Bellicum to collaborate on T-cell therapies

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Adaptimmune, Bellicum to collaborate on T-cell therapies

Adaptimmune Therapeutics PLC and Bellicum Pharmaceuticals Inc. signed a deal to collaborate on the evaluation, development and commercialization of next-generation T-cell therapies.

The companies said they agreed to utilize Adaptimmune's affinity-optimized SPEAR T-cells to evaluate Bellicum's GoTCR technology for the potential to create enhanced T-cell receptor product candidates. Based on the results of the pre-clinical proof-of-concept phase, the companies will move to a two-target co-development and co-commercialization phase.